Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines

CONCLUSION: The findings showed that high doses of current MERS-CoV vaccine candidates conferred better immunogenicity than low doses and that there were no differences in the safety of the vaccines.PMID:37004348 | PMC:PMC10050282 | DOI:10.1016/j.intimp.2023.109998

Source: International Immunopharmacology - April 2, 2023 Category: Allergy & Immunology Authors: Mahmoud Kandeel Mohamed A Morsy Hany M Abd El-Lateef Mohamed Marzok Hossam S El-Beltagi Khalid M Al Khodair Ibrahim Albokhadaim Katharigatta N Venugopala Source Type: research